Benlong Yang

Benlong Yang

Auto-generated profile, based on publicly available information

Benlong Yang

Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai Fudan University Shanghai Cancer Center Shanghai China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in International Journal of Surgery
Verified
Journal Article
Open access
SWSi-Yu Wu
Si-Yu Wu
JLJian-Wei Li
Jian-Wei Li
YWYujie Wang
Yujie Wang
KJKai-Rui Jin
Kai-Rui Jin
BYBen-Long Yang
Ben-Long Yang
GLGuangyu Liu
Guangyu Liu
Background: Targeted axillary dissection (TAD) includes biopsy of clipped lymph node and sentinel lymph nodes. However, clinical evidence regarding clinical feasibility and oncological safety of non-radioactive TAD in a real-world cohort remains limited. Methods: In this prospective registry study, patients routinely underwent clip insertion into biopsy-confirmed lymph node. Eligible patients received neoadjuvant chemotherapy (NACT) followed by axillary surgery. Main endpoints included the false-negative rate (FNR) of TAD and nodal recurrence rate. Results: Data from 353 eligible patients were analyzed. After completion of NACT, 85 patients directly proceeded to axillary lymph node dissection (ALND), furthermore, TAD with or without ALND was performed in 152 and 85 patients, respectively. Overall detection rate of clipped node was 94.9% (95%CI, 91.3%-97.4%) and FNR of TAD was 12.2% (95%CI, 6.0%-21.3%) in our study, with FNR decreasing to 6.0% (95%CI, 1.7%-14.6%) in initially cN1 patients. During a median follow-up of 36.6 months, 3 nodal recurrences occurred (3/237 with ALND; 0/85 with TAD alone), with a three-year freedom-from-nodal-recurrence rate of 100.0% among the TAD-only patients and 98.7% among the ALND patients with axillary pathologic complete response (P=0.29). Conclusions: TAD is feasible in initially cN1 breast cancer patients with biopsy-confirmed nodal metastases. ALND can safely be foregone in patients with negativity or a low volume of nodal positivity on TAD, with a low nodal failure rate and no compromise of three-year recurrence-free survival.

1 January 2022 in Oncologie
Verified
Journal Article
Open access
XZXujie Zhou
Xujie Zhou
YSYuting Sang
Yuting Sang
JCJiajian Chen
Jiajian Chen
MMMiao Mo
Miao Mo
JHJianjing Hou
Jianjing Hou
JWJiong Wu
Jiong Wu
Background: To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in the contemporary era with those in the past era. Patients and Methods: This retrospective study included 14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to 2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was made on the changing patterns of recurrence for patients with different molecular subtypes changed between the two treatment eras. Kaplan–Meier survival curves were generated, and the hazard function was used to estimate the annual recurrence hazard. Results: By the end of follow-up (median, 68.1 months), 1429 patients (9.77%) experienced recurrence and metastasis. The annual recurrence risks of the entire population and each molecular type in 2013–2016 were reduced compared with those in 2008–2012. Luminal A and triple-negative patients in 2013–2016 showed a significantly lower recurrence hazard curve than those in 2008–2012. The recurrence hazard curve of luminal B (HER2−) and HER2+ subtypes was lower in 2013–2016 than in 2008–2012. The recurrence risk of the luminal B (HER2+) subtype was reduced substantially during 2013–2016, showing a delay of two years. Conclusions: With early detection of disease recurrence and improved treatment strategies, the recurrence patterns of different molecular subtypes of breast cancer have changed. The time-varying recurrence patterns observed during the contemporary era are significant for treatment decision-making and clinical trial planning.

1 January 2024 in Cancer Medicine
Verified
Journal Article
Open access
MXMin Xiong
Min Xiong
XWXuliren Wang
Xuliren Wang
DLDouwaner Liu
Douwaner Liu
BXBingqiu Xiu
Bingqiu Xiu
QZQi Zhang
Qi Zhang
JWJiong Wu
Jiong Wu
Background: Gene mutations play a crucial role in the occurrence and development of tumors, particularly in breast cancer (BC). Neoadjuvant therapy (NAT) has shown greater clinical benefit in HER2‐positive breast cancer. However, further clinical investigation is needed to fully understand the correlation between genetic mutations and NAT efficacy and the long‐term prognosis in HER2‐positive BC.Methods: This was a retrospective cohort study of 222 patients receiving NAT between 2017 and 2021 in the Department of Breast Surgery of Fudan University Shanghai Cancer Center. Tumor samples from these patients were subjected to Next Generation Sequencing (NGS) to analyze mutations in 513 cancer‐related genes. This study aimed to investigate the association between these genetic mutations and postoperative pathological complete response (pCR), as well as their impact on disease‐free survival (DFS).Results: In total, 48.65% patients reached pCR, ER‐negative status (p < 0.001), PR‐negative status (p < 0.001), Ki67 ≥ 20 (p = 0.011), and dual‐targeted therapy (p < 0.001) were all associated with enhanced pCR rates. The frequency of somatic alterations in TP53 (60%), PIK3CA (15%), and ERBB2 (11%) was highest. In the HER2+/HR‐ cohort, patients who achieved pCR had a significant benefit in prognosis (HR = 3.049, p = 0.0498). KMT2C (p = 0.036) and TP53 (p = 0.037) mutations were significantly increased in patients with DFS events. Moreover, TP53 mutations had prognostic significance in HER2‐positive BC patients with HR‐negative (HR = 3.712, p = 0.027) and pCR (HR = 6.253, p = 0.027) status and who received herceptin‐only targeted therapy (HR = 4.145, p = 0.011).Conclusions: The genetic mutation profiles of Chinese HER2+ patients who received NAT were discrepant with respect to HR status or DFS events. TP53 mutations have significant prognostic value in patients with NAT for HER2‐positive BC and patients benefit differently depending on HR status, the neoadjuvant regimen and response, which highlights the significance of genetic factors in treatment customization based on individual genetic and clinical characteristics.

19 May 2023 in Annals of Plastic Surgery
Verified
Journal Article
Open access
WCWEI-RU CHI
WEI-RU CHI
QZQi Zhang
Qi Zhang
LLLun Li
Lun Li
MCMing Mb Chen
Ming Mb Chen
BXBingqiu Xiu
Bingqiu Xiu
JWJiong Wu
Jiong Wu
Background: Breast reconstruction has become an integral component of breast cancer treatment, especially for patients who are unable to undergo breast-conserving surgery after neoadjuvant chemotherapy (NAC). We analyzed factors influencing the type of immediate reconstruction surgery after NAC, as well as the complication rates for each surgery type. Methods: The study included patients with breast cancer who underwent mastectomy following NAC from 2010 to 2021. Clinicopathological characteristics, unplanned reoperation rates, and the duration of postoperative hospitalization were analyzed in patients undergoing autologous tissue reconstruction (ATR, n = 127), implant-based reconstruction (IBR, n = 60), and combined autologous tissue and implant reconstruction (n = 60). Results: A total of 1651 patients who received NAC before mastectomy were enrolled. Among them, 247 (15.0%) patients underwent immediate reconstruction (IR), whereas 1404 underwent mastectomy only. Patients in the IR group were younger (P < 0.001), had lower body mass index (P < 0.001), and exhibited earlier clinical (P = 0.003) and nodal (P < 0.001) stage than those in the non-IR group. Patients in the ATR group were older (P < 0.001) and had higher body mass index (P = 0.007), larger tumor size (P = 0.024), and more frequent childbearing history (P = 0.011) than those in the other groups. Complications resulting in unplanned reoperations were more frequent in the IBR group (P = 0.039). The duration of postoperative hospitalization was longest after ATR (P = 0.008). Conclusions: Age and clinical tumor/nodal stage at presentation are associated with IR for patients undergoing mastectomy after NAC. For patients undergoing IR after NAC, ATR may be safer and more suitable than IBR.